Physician profile
Mohammadali Anwar
NPI 1700269230
$1,242.08
in general payments reported to CMS, 2019-2025
16 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.65 · 2022: $260 · 2023: $171 · 2024: $347 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881 · Education: $26.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.53 |
| Education | $26.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $197.24 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Astrazeneca Pharmaceuticals LP | $194.80 | 2022-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $153.71 | 2021-2025 | Auryxia, Vafseo |
| Travere Therapeutics, INC. | $147.55 | 2022-2025 | Filspari |
| Opko Pharmaceuticals, LLC | $101.48 | 2021-2025 | Rayaldee |
| Lilly USA, LLC | $62.80 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $57.04 | 2021-2025 | |
| Novo Nordisk INC | $53.41 | 2025 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $51.57 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $45.77 | 2022 | |
| Vifor Pharma, INC. | $40.81 | 2022-2023 | Korsuva, Veltassa |
| Glaxosmithkline, LLC. | $36.12 | 2022-2023 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.26 | 2024 | Jardiance |
| Calliditas Therapeutics US INC. | $26.52 | 2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $23.16 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $20.84 | 2024 | Velphoro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammadali Anwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.